Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

Sales of blockbuster weight-loss drugs have surged in 2024 and are projected to continue rising in the coming years. The ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

Novo Nordisk has announced billions of dollars worth of investments this year, including $4.1 billion to build a U.S. facility to fill injection pens for Wegovy and diabetes drug Ozempic.

Novo Nordisk has announced billions of dollars worth of investments this year, including $4.1 billion to build a U.S. facility to fill injection pens for Wegovy and diabetes drug Ozempic. Shares in ...

The holding company, which oversees drugmaker Novo Nordisk, said on Saturday that all regulatory ... intended to boost Novo’s popular GLP-1 weight loss drugs Ozempic and Wegovy, as injection pens are ...

Ozempic- and Wegovy-like drugs used to treat ... GLP-1 drugs, like Danish drugmaker Novo Nordisk’s semaglutide, have been game changers in obesity treatment, with demand across the globe soaring.